L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-
Neuroendocrine Neoplasm
Explore 59 assets in Neuroendocrine Neoplasm →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07262957CT.gov Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA) | — | Recruiting | — | — | — |
NCT06345079CT.gov Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours | — | Recruiting | — | — | — |
NCT05477576CT.gov Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | — | Recruiting | — | — | — |
NCT00781911CT.gov A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | — | Completed | — | — | — |
NCT00569127CT.gov Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor | — | Active Not Recruiting | — | — | — |
NCT00363051CT.gov Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroendocrine Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- (this asset) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Approved | B · 63 |
| Fluorouracilum | ITM Solucin GmbH | P3 | BB |
| Irinotecan | First Affiliated Hospital Xi'an Jiaotong University | P4 | BB |
| Cabozantinib | Fox Chase Cancer Center | P3 | BB |
| Surufatinib | Shanghai Changzheng Hospital | P3 | BB |
| Everolimus | Exelixis | P3 | BB |
| Oxodotreotide | Fundación de investigación HM | P3 | BB |
| Carboplatin | First Affiliated Hospital Xi'an Jiaotong University | P4 | B |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | B |
+42 more in the Neuroendocrine Neoplasm cohort
Other indications for L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Esophageal Varices | — | P4 | BB · 71 |
| Diarrheal Disease | — | P3 | BB · 71 |
| Cirrhosis Of Liver | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- in Neuroendocrine Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/l-cysteinamide-d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-n-2-hydroxy-1-hydroxymethylpropyl-cyclic-2-7-disulfide-r-rr-neuroendocrine-neoplasm-106027
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →